Bluebird Bio, a US-based gene therapy specialist, plans to float on the Nasdaq stock exchange with a market capitalization of about $328m.

Bluebird plans to offer 5 million shares at between $14 and $16 each, with a further $750,000 shares available if demand is strong.

Investment banks JP Morgan and BoA Merrill Lynch are Bluebird’s lead underwriters for the initial public offering (IPO), with legal counsel from Goodwin Procter and Ropes & Gray.

Bluebird Bio  posted a $6.5m net loss on $1.1m of revenue in the first three months of the year.

Bluebird Bio has raised around $130 million in VC funding, from Third Rock Ventures (28.1% pre-IPO stake), TVM Capital (14.3%), Fidelity Investments (11.8%), Arch Venture Partners (10.6%), Capital Research & Management Co. (9.2%), Forbion Capital Partners (7.4%), Deerfield Partners, RA Capital, Ramius Capital Group and Shire PLC.

In August last year, Bluebird Bio has raised $60m in a Series…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?